Sugi Predict
/ Targets
/ PSMB2
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to PSMB2 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease |
PHASE4 | UNKNOWN |
| Doxorubicin and Bortezomib in Treating Patients With Liver Cancer |
PHASE2 | COMPLETED |
| A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma |
PHASE2 | WITHDRAWN |
| A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma |
PHASE2 | COMPLETED |
| Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors |
PHASE2 | COMPLETED |
| Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes |
PHASE2 | UNKNOWN |
| Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis |
PHASE2 | RECRUITING |
| The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy |
PHASE2 | NOT_YET_RECRUITING |
| A Prevention Trial in Subjects at High Risk for Breast Cancer |
PHASE2 | COMPLETED |
| A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer |
PHASE2 | COMPLETED |
| Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer |
PHASE2 | COMPLETED |
| Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas |
PHASE2 | COMPLETED |
| Relapsed and/or Refractory Non-Hodgkin Lymphoma Study |
PHASE2 | WITHDRAWN |
| Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma |
PHASE1 | COMPLETED |
| PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck |
PHASE1 | COMPLETED |
| Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors |
PHASE1 | COMPLETED |
| GO-203-2C + Bortezomib For Relapsed Or Refractory MM |
PHASE1 | WITHDRAWN |
| Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer |
PHASE1 | COMPLETED |
| Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma |
PHASE1 | COMPLETED |
| PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma |
PHASE1 | COMPLETED |
| Bortezomib, Fluorouracil, and Leucovorin Calcium in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery |
PHASE1 | COMPLETED |
| Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment |
nan | UNKNOWN |
| Cardiovascular Complications of Carfilzomib Treatment |
nan | UNKNOWN |
| Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors |
nan | NOT_YET_RECRUITING |
| Low Dose Melphalan and Bortezomib for AML and High-Risk MDS |
nan | COMPLETED |
| The PREServation of MUScle Function in Critically Ill Patients (PRESMUS) |
nan | UNKNOWN |
| Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT) |
nan | UNKNOWN |
| Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract |
nan | UNKNOWN |
| The Pathophysiology of Bortezomib Induced Peripheral Neuropathy |
nan | UNKNOWN |
| Establishment of Human Cellular Disease Models for Wilson Disease |
nan | COMPLETED |
Related proteins — ESM-2 sequence neighbours (a PSMB2 binder may also engage these)